Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
